Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant abemaciclib and giredestrant in ER-positive, HER2-negative early breast cancer
2023-510153-42-00Phase 2Authorised
- Sponsor
- Fondazione Oncotech
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of giredestrant and abemaciclib in breast cancer, sponsored by Fondazione Oncotech. Primary endpoint: Central complete cell-cycle arrest rate. Planned start Nov 2024; status: authorised.
02
Drugs
giredestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-510153-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510153-42-00.